Key Points
- Insider sale: Sherry Korczynski sold 8,750 Aquestive Therapeutics shares for approximately $45,675 under a pre-arranged Rule 10b5-1 plan, reducing direct ownership by 3.58% to 235,689 shares.
- Stock and earnings: AQST opened at $4.78 after trading down 4.2%. The company reported a quarterly loss of $0.18 per share, missing estimates, though revenue of $13.82 million exceeded forecasts.
- Analyst outlook: Despite mixed ratings, the stock carries a consensus “Moderate Buy” rating with an average price target of $9.17, well above its current trading level.
Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) insider Sherry Korczynski sold 8,750 shares of the firm's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $5.22, for a total transaction of $45,675.00. Following the completion of the transaction, the insider directly owned 235,689 shares in the company, valued at $1,230,296.58. This represents a 3.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Aquestive Therapeutics Trading Down 4.2%
AQST stock opened at $4.78 on Friday. Aquestive Therapeutics, Inc. has a 12-month low of $2.93 and a 12-month high of $7.55. The business's 50-day moving average is $4.39 and its 200 day moving average is $4.26. The stock has a market cap of $599.94 million, a price-to-earnings ratio of -7.35 and a beta of 1.48.
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.18) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.08). The business had revenue of $13.82 million during the quarter, compared to analyst estimates of $11.42 million. As a group, equities analysts forecast that Aquestive Therapeutics, Inc. will post -0.5 EPS for the current fiscal year.
Analyst Ratings Changes
Several research firms recently commented on AQST. Wall Street Zen raised Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. HC Wainwright reaffirmed a "buy" rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Monday, August 24th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $11.00 target price on shares of Aquestive Therapeutics in a report on Thursday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.17.
Get Our Latest Report on AQST
Institutional Investors Weigh In On Aquestive Therapeutics
Large investors have recently made changes to their positions in the stock. WINTON GROUP Ltd purchased a new stake in shares of Aquestive Therapeutics in the second quarter valued at approximately $210,000. Engineers Gate Manager LP lifted its position in Aquestive Therapeutics by 20.5% during the second quarter. Engineers Gate Manager LP now owns 49,879 shares of the company's stock worth $207,000 after buying an additional 8,496 shares in the last quarter. Wedbush Securities Inc. acquired a new position in Aquestive Therapeutics during the second quarter worth $60,000. Wellington Management Group LLP boosted its stake in Aquestive Therapeutics by 4.0% during the second quarter. Wellington Management Group LLP now owns 301,647 shares of the company's stock worth $1,255,000 after buying an additional 11,587 shares during the last quarter. Finally, Beacon Pointe Advisors LLC acquired a new position in Aquestive Therapeutics during the second quarter worth $252,000. 32.45% of the stock is currently owned by hedge funds and other institutional investors.
Aquestive Therapeutics Company Profile
(
Get Free Report)
Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.
The company's lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
